LGM Pharma unveils enhanced analytical testing services and expands CDMO portfolio with additional suppository manufacturing capabilities

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced a significant enhancement of its capabilities: a 50% expansion and an investment exceeding $2 million in its standalone offering for Analytical Testing Services (ATS) alongside the introduction of new suppository manufacturing capabilities to its contract development and manufacturing (CDMO) portfolio.

Related Keywords

California ,United States ,Texas ,Irvine ,Laura Thomson ,Shailesh Vengurlekar ,Prasad Raje ,Analytical Testing Services ,Quality Regulatory Affairs ,Chief Executive Officer ,Senior Vice President ,Regulatory Affairs ,